CE
CERO.US CERo Therapeutics Holdings, Inc. Common Stock
- Market cap
- USD 358K
- P/E
- 0.0x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CERO.US undervalued?
Graham numberThe Graham number of CERo Therapeutics Holdings, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CERo Therapeutics Holdings, Inc. Common Stock fundamental analysis
No fundamental analysis for CERo Therapeutics Holdings, Inc. Common Stock yet.
CERo Therapeutics Holdings, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Full company profileCERo Therapeutics Holdings, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CERo Therapeutics Holdings, Inc. Common Stock annual financial statements
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | - | 0.00 | - |
| Gross Profit | - | - | -1.12M | -1.16M | -1.09M | - |
| Operating Income | -332K | -2.91M | -2.93M | -15.3M | -18.5M | -15.8M |
| EBITDA | 403K | -1.83M | -1.32M | -6.57M | -17.4M | -15.1M |
| Net Income | -316K | -668K | -2.54K | -7.73M | -19.9M | -3.86M |
| EPS | -43 | -91 | -0.34 | -64 | -4.71 | 0.00 |
| Balance Sheet | ||||||
| Total Assets | 180M | 42.4M | 5.13M | 6.21M | 3.64M | 1.83M |
| Total Liabilities | 9.25M | 39.9M | 47.2M | 8.10M | 9.09M | 20.7M |
| Shareholders' Equity | 171M | 2.47M | -5.76M | -1.89M | -5.45M | -18.8M |
| Cash & Short-term Investments | 1.10M | 42.1M | 1.60M | 3.33M | 1.66M | 531K |
| Total Debt | 3.60M | 650K | 1.56M | 1.58M | 699K | 8.79M |
| Cash Flow | ||||||
| Operating Cash Flow | -697K | -1.09M | -5.79M | -5.79M | -16.1M | -10.8M |
| Capital Expenditure | 613K | 694K | 3.00 | 1.00 | 0.00 | 8.00 |
| Free Cash Flow | -1.31M | -1.79M | -5.79M | -5.79M | -16.1M | -10.8M |
| Ratios | ||||||
| ROE | -0.2% | -27.0% | - | - | - | - |
| ROA | -0.2% | -1.6% | 0.0% | -124.6% | -547.1% | -211.1% |
| Debt to Equity | 0.02x | 0.26x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
CERo Therapeutics Holdings, Inc. Common Stock dividends
CERo Therapeutics Holdings, Inc. Common Stock has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Jun 13, 2025.
Who owns CERo Therapeutics Holdings, Inc. Common Stock
- Insiders 2.95%
- Institutions 0.09%
- Public & others 96.96%
- Shares outstanding 71.6M
- Free float 69.6M
CERo Therapeutics Holdings, Inc. Common Stock company profile
- Company name
- CERo Therapeutics Holdings, Inc. Common Stock
- Ticker
- CERO.US
- Exchange
- USA Stocks
- Listed since
- Feb 15, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 201 Haskins Way, South San Francisco, CA, United States, 94080
- Phone
- 650 407 2376
- Website
- cero.bio
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc. Common Stock management
4- Mr. Christopher B. Ehrlich M.B.A.CEO & Chair · born 1970
- Mr. Andrew Albert Kucharchuk M.B.A.Chief Financial Officer · born 1981
- Dr. Kristen Pierce Ph.D.Chief Development Officer · born 1971
- Dr. Lawrence Corey M.D.Co-founder & Head of Scientific Advisory Board · born 1947